Enanta Pharmaceuticals Inc
NASDAQ:ENTA

Watchlist Manager
Enanta Pharmaceuticals Inc Logo
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Watchlist
Price: 12.95 USD 2.37% Market Closed
Market Cap: $373.7m

Net Margin

-125.4%
Current
Improving
by 33.7%
vs 3-y average of -159%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-125.4%
=
Net Income
$-81.9m
/
Revenue
$65.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-125.4%
=
Net Income
$-81.9m
/
Revenue
$65.3m

Peer Comparison

Country Company Market Cap Net
Margin
US
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
365.1m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 15 072 companies
14th percentile
-125.4%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Enanta Pharmaceuticals Inc
Glance View

Market Cap
373.7m USD
Industry
Biotechnology

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The firm has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The firm has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The firm's subsidiary is Enanta Pharmaceuticals Security Corporation.

ENTA Intrinsic Value
8.74 USD
Overvaluation 32%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-125.4%
=
Net Income
$-81.9m
/
Revenue
$65.3m
What is Enanta Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Enanta Pharmaceuticals Inc is -125.4%, which is above its 3-year median of -159%.

How has Net Margin changed over time?

Over the last 3 years, Enanta Pharmaceuticals Inc’s Net Margin has increased from -141.3% to -125.4%. During this period, it reached a low of -187.8% on Dec 31, 2023 and a high of -125.4% on Oct 30, 2025.

Back to Top